CA3168001A1 - Glp-1r and gcgr agonists, formulations, and methods of use - Google Patents

Glp-1r and gcgr agonists, formulations, and methods of use Download PDF

Info

Publication number
CA3168001A1
CA3168001A1 CA3168001A CA3168001A CA3168001A1 CA 3168001 A1 CA3168001 A1 CA 3168001A1 CA 3168001 A CA3168001 A CA 3168001A CA 3168001 A CA3168001 A CA 3168001A CA 3168001 A1 CA3168001 A1 CA 3168001A1
Authority
CA
Canada
Prior art keywords
dose
pharmaceutical dosage
optionally
administration
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3168001A
Other languages
English (en)
French (fr)
Inventor
John Nestor
Vyjayanthi Krishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spitfire Pharma LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3168001A1 publication Critical patent/CA3168001A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3168001A 2020-02-21 2021-02-21 Glp-1r and gcgr agonists, formulations, and methods of use Pending CA3168001A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062980093P 2020-02-21 2020-02-21
US62/980,093 2020-02-21
US202063122108P 2020-12-07 2020-12-07
US63/122,108 2020-12-07
US202163133540P 2021-01-04 2021-01-04
US63/133,540 2021-01-04
PCT/US2021/018947 WO2021168386A1 (en) 2020-02-21 2021-02-21 Glp-1r and gcgr agonists, formulations, and methods of use

Publications (1)

Publication Number Publication Date
CA3168001A1 true CA3168001A1 (en) 2021-08-26

Family

ID=77391258

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3168001A Pending CA3168001A1 (en) 2020-02-21 2021-02-21 Glp-1r and gcgr agonists, formulations, and methods of use

Country Status (11)

Country Link
US (2) US20210290732A1 (cg-RX-API-DMAC10.html)
EP (1) EP4106796A4 (cg-RX-API-DMAC10.html)
JP (2) JP7752619B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220143923A (cg-RX-API-DMAC10.html)
CN (1) CN115427065A (cg-RX-API-DMAC10.html)
AU (1) AU2021224246A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022016470A2 (cg-RX-API-DMAC10.html)
CA (1) CA3168001A1 (cg-RX-API-DMAC10.html)
IL (1) IL295744A (cg-RX-API-DMAC10.html)
MX (1) MX2022010320A (cg-RX-API-DMAC10.html)
WO (1) WO2021168386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4286400A3 (en) * 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014081872A1 (en) * 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
US20230317230A1 (en) * 2019-05-02 2023-10-05 Closed Loop Medicine Ltd. Method for treating obesity
CN117202924A (zh) * 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
US20240148879A1 (en) * 2021-02-21 2024-05-09 Spitfire Pharma Llc Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
KR20240118786A (ko) * 2021-12-01 2024-08-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Glp-1 및 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
KR20250067161A (ko) * 2022-09-14 2025-05-14 스핏파이어 파마, 엘엘씨 Glp-1r 및 gcgr 효능제를 사용하여 지방간 질환을 앓는 피험체에서 체중을 감소시키기 위한 치료 요법 및 방법
WO2024098071A1 (en) * 2022-11-05 2024-05-10 Spitfire Pharma Llc Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280814A1 (en) 2004-09-17 2008-11-13 Novo Nordisk A/S Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
EP4286400A3 (en) * 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014081872A1 (en) * 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
EP2922877B1 (en) * 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
BR112015025464A2 (pt) * 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CN117582516A (zh) * 2014-05-28 2024-02-23 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
PE20170471A1 (es) 2014-06-13 2017-05-14 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados
JP2017517549A (ja) * 2014-06-13 2017-06-29 サノフイ 活性薬剤成分のナノカプセル製剤
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
FI3322437T3 (fi) * 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
AU2019205905B2 (en) * 2018-01-03 2024-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of NASH and other disorders

Also Published As

Publication number Publication date
AU2021224246A1 (en) 2022-09-15
JP2023514992A (ja) 2023-04-12
CN115427065A (zh) 2022-12-02
KR20220143923A (ko) 2022-10-25
EP4106796A1 (en) 2022-12-28
EP4106796A4 (en) 2024-04-17
WO2021168386A1 (en) 2021-08-26
JP2026021305A (ja) 2026-02-10
US20210290732A1 (en) 2021-09-23
IL295744A (en) 2022-10-01
BR112022016470A2 (pt) 2022-11-22
US20250262280A1 (en) 2025-08-21
JP7752619B2 (ja) 2025-10-10
MX2022010320A (es) 2023-01-30

Similar Documents

Publication Publication Date Title
US12257229B2 (en) Peptide pharmaceuticals for treatment of NASH and other disorders
US20250262280A1 (en) GLP-1R and GCGR Agonists, Formulations, and Methods of Use
US20240148879A1 (en) Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
US20250134963A1 (en) Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
US20240269238A1 (en) Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist
US12171806B2 (en) Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
US20240277815A1 (en) Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist
EP4611792A1 (en) Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist
HK40101792A (en) Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250214

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250214

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250214

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250730

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250730

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20251016

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251016

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20251016

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251016

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251016

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251016

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251016

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251016